ArticleCurrent microbiology2026
Core Proteome Subtractive Genomics Reveals Potential Therapeutic Targets in Bacillus anthracis.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bacillus anthracis, a Gram-positive, spore-forming bacterium, poses significant public health risks due to its zoonotic potential and historical use in bioterrorism. Pathogenicity of B. anthracis is primarily attributed to its genetic components, including the essential plasmids pXO1 and pXO2. The pXO1 plasmid encodes toxic factors, while pXO2 facilitates immune evasion. The zoonotic potential, as well as potential bio-threat, necessitates investigation into novel therapeutic targets. Through metabolic network analysis, docking, and notably subtractive genomics, researchers have effectively pinpointed pathogen-specific target proteins essential for drug development. Subtractive genomics, in particular, stands out for its cost-effectiveness and ability to identify non-host homologous targets. In this study, we used a core proteome immunoinformatic approach to identify potential therapeutic targets in B. anthracis. A total of 3987 proteins were found to be conserved in B. anthracis and among them, 388 were essential, non-human homologous proteins. These proteins were then subjected to localization and pathway analysis which resulted in 79 unique pathway proteins. Through PPI and druggability analysis, we had identified 17 strain-independent therapeutic target proteins. All the identified proteins are non-homologous to human proteins and, therefore, are potential targets for drug development. These potential target proteins are involved primarily in cell division, peptidoglycan biosynthesis, and putative flagellar assembly, which are essential for bacterial survival and pathogenicity. These identified target proteins could be the foundation for the development of therapeutics against human anthrax.
Indexed as
Identifiers
42821116What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.